Electromed, Inc. income statement
In fiscal 2026, Electromed, Inc. reported revenue of $73.8m, up 15.3% on the year before, operating income of $13.9m (a 18.8% margin) and net income of $11.3m, or $1.30 per diluted share. Every line below comes from the company's 10-K and 10-Q filings; column headings link to the filing.
Income statement
| Fiscal year | 2011Jun 2011 | 2012Jun 2012 | 2013Jun 2013 | 2014Jun 2014 | 2015Jun 2015 | 2016Jun 2016 | 2017Jun 2017 | 2018Jun 2018 | 2019Jun 2019 | 2020Jun 2020 | 2021Jun 2021 | 2022Jun 2022 | 2023Jun 2023 | 2024Jun 2024 | 2025Jun 2025 | 2026Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 19 | 20 | 15 | 15 | 19 | 23 | 26 | 28 | 31 | 32 | 36 | 42 | 48 | 55 | 64 | 74 |
| Cost of revenue | 5 | 5 | 5 | 5 | 6 | 5 | 5 | 7 | 7 | 7 | 8 | 10 | 12 | 13 | 14 | 16 |
| Gross profit | 14 | 14 | 10 | 11 | 14 | 18 | 21 | 22 | 24 | 25 | 27 | 31 | 37 | 42 | 50 | 58 |
| Research and development | 1 | 1 | 1 | 0 | 0 | 0 | 1 | 0 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 |
| Selling, general and administrative | 11 | 13 | 12 | 11 | 12 | 14 | 16 | 19 | 20 | 20 | 22 | 27 | 32 | 34 | 39 | 43 |
| Operating income | 2 | 1 | −2 | −1 | 1 | 3 | 4 | 3 | 3 | 5 | 3 | 3 | 4 | 7 | 10 | 14 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | — | — | — | — | — | — | — | — | — | — | — |
| Net interest income | — | — | — | — | −0 | −0 | −0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | — | — |
| Income before tax | 2 | 0 | −2 | −1 | 1 | 3 | 4 | 3 | 3 | 5 | 3 | 3 | 4 | 7 | 10 | 14 |
| Income tax | 1 | 0 | −1 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 3 | 3 |
| Net income | 1 | 0 | −1 | −1 | 1 | 2 | 2 | 2 | 2 | 4 | 2 | 2 | 3 | 5 | 8 | 11 |
| Diluted EPS | $0.13 | $0.02 | −$0.16 | −$0.16 | $0.13 | $0.27 | $0.26 | $0.21 | $0.23 | $0.47 | $0.27 | $0.26 | $0.36 | $0.58 | $0.85 | $1.30 |
| Diluted shares (average) | 8m | 8m | 8m | 8m | 8m | 8m | 8m | 9m | 9m | 9m | 9m | 9m | 9m | 9m | 9m | 9m |
| EBITDA | 2 | 1 | −1 | −0 | 2 | 4 | 4 | 3 | 4 | 6 | 4 | 3 | 5 | 7 | 11 | 15 |
| Quarter | 2025 Q1Sept 2024 | 2025 Q2Dec 2024 | 2025 Q3Mar 2025 | 2025 Q4Jun 2025 | 2026 Q1Sept 2025 | 2026 Q2Dec 2025 | 2026 Q3Mar 2026 | 2026 Q4Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 15 | 16 | 16 | 17 | 17 | 19 | 19 | 19 |
| Cost of revenue | 3 | 4 | 3 | 4 | 4 | 4 | 4 | 4 |
| Gross profit | 11 | 13 | 12 | 14 | 13 | 15 | 15 | 15 |
| Research and development | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Selling, general and administrative | 9 | 10 | 10 | 10 | 10 | 11 | 11 | 11 |
| Operating income | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 |
| Net interest income | 0 | 0 | — | — | — | — | — | — |
| Income before tax | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 |
| Income tax | 1 | 1 | 0 | 1 | 1 | 1 | 1 | 1 |
| Net income | 1 | 2 | 2 | 2 | 2 | 3 | 3 | 3 |
| Diluted EPS | $0.16 | $0.22 | $0.21 | $0.26 | $0.25 | $0.32 | $0.35 | $0.39 |
| EBITDA | 2 | 3 | 2 | 3 | 3 | 4 | 4 | 4 |
Compare with peers
- Avita Medical, Inc. income statement
- PRO DEX Inc income statement
- Tela Bio, Inc. income statement
- Sight Sciences, Inc. income statement
- Pulmonx Corp income statement
Head to head: ELMD vs RCELELMD vs PDEXELMD vs TELA
More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies